+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
E

Actively Recruiting

Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.

Age: 18Years +FEMALEPhase 3
191 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of regimens containing quabodepistat for treating rifampicin-resistant or multidrug-resistant pulmonary tuberculosis in this Phase 3, randomized, open-label, multicenter trial. Participants are divided into two groups based on fluoroquinolone susceptibility and randomized to receive either experimental or control treatment regimens. The study aims to provide shorter, well-tolerated treatment options for drug-resistant tuberculosis. Participants with fluoroquinolone-susceptible tuberculosis are randomized to a 4-month experimental regimen including bedaquiline, pretomanid, quabodepistat, and moxifloxacin or a 6-month control regimen with bedaquiline, pretomanid, linezolid, and moxifloxacin. Those with fluoroquinolone-resistant tuberculosis receive either a 6-month experimental regimen of bedaquiline, pretomanid, and quabodepistat or a 6-month control regimen of bedaquiline, pretomanid, and linezolid. Doses vary by drug and regimen, with some adjustments permitted for toxicity. Participants are followed for approximately 16 months after randomization, with evaluations including sputum samples, chest X-rays, and monitoring of adverse events. The main outcome measured is the proportion of participants with unfavorable outcomes at 12 months post-randomization. Other assessments include treatment-emergent adverse events, sputum culture conversion, relapse, and reinfection. Follow-up visits may extend to week 72 for ongoing safety or relapse monitoring.

Age: 14Years +All GendersPhase 3
42 locations
C

Actively Recruiting

Researchers are conducting a prospective, noninterventional, single-arm study to collect biometry and aberrometry data using a next-generation biometer called Unity DX. The study includes four distinct groups of participants with cataracts, some with previous or planned implantation of Alcon intraocular lenses and others with prior refractive surgery or keratoconus. This multicenter study will take place in the US, India, Spain, and the Philippines. Participants will undergo measurements with the Unity DX and SMARTCataract DX SCDX Biometer, along with either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer, depending on the site. Subjects include eyes previously implanted with Alcon monofocal or multifocal presbyopia-correcting IOLs, planned implantation of monofocal or toric IOLs, prior refractive surgery with planned implantation, and eyes with keratoconus. During the study, participants will have various assessments to collect data including optical biometry and eye aberrometry. The main measurement is Manifest Refraction Spherical Equivalent MRSE assessed at different time points depending on the group, including screening and postoperative periods. Participants will attend study visits as required, with data collected through standard clinical assessments to evaluate the devices performance in capturing eye measurements.

Age: 18Years +All Genders
5 locations
E

Actively Recruiting

This research aims to compare the visual outcomes of a new trifocal intraocular lens IOL model LPYWT0 with a commercially available trifocal IOL called Clareon PanOptix Pro Model PXYWT0. The study involves adults with cataracts in both eyes who are undergoing cataract surgery. The purpose is to understand how well each lens performs after surgery in terms of vision clarity. Participants will receive cataract surgery in both eyes. One eye will be implanted with the investigational LPYWT0 IOL and the other eye with the marketed PXYWT0 IOL. The second eye surgery will be scheduled between 7 and 14 days after the first eye surgery. The study is randomized so which eye receives which lens is determined by chance. The lenses are designed to stay in the eye permanently after implantation. During the study, participants will attend nine scheduled visits over about seven months. Researchers will assess vision using tests such as the Best Corrected Distance Visual Acuity at six months after surgery. Other evaluations will include eye exams and safety monitoring throughout the participation period. The study is conducted in India and the Philippines and aims to gather detailed data on the performance of these two lens types.

Age: 22Years +All GendersPhase Not Applicable
5 locations
P

Actively Recruiting

Researchers are studying adults with pulmonary hypertension associated with interstitial lung disease PH-ILD to evaluate the effects of a 24-week daily treatment using Treprostinil Palmitil Inhalation Powder TPIP compared to a placebo. This phase 3, randomized, double-blind, placebo-controlled study aims to assess how TPIP impacts exercise capacity in this group. Participants will receive either TPIP once daily, starting at 80 micrograms and increasing to a maximum tolerated dose of 1280 micrograms, or a placebo inhaled via a capsule-based dry powder inhaler. The treatment period lasts for 24 weeks, and both groups use the same type of inhalation device to maintain blinding. During the study, participants will undergo assessments including the 6-minute walk test to measure exercise capacity and blood tests to track heart-related biomarkers like NT-proBNP. Researchers will monitor clinical worsening events, adverse effects, and plasma drug levels throughout the 24-week treatment. The study is designed to provide detailed information about TPIPs impact on PH-ILD over this period.

Age: 18Years +All GendersPhase 3
186 locations
S

Actively Recruiting

Researchers are evaluating the performance and safety of the JASPER Robotic Surgical System during cataract surgery in adults aged 55 to 80 years. This prospective, open-label clinical study focuses on how well this robotically assisted device helps ophthalmic surgeons perform cataract procedures. Participants will undergo cataract surgery using the JASPER Robotic Surgical System. This device is designed to assist surgeons during the operation. The study follows patients from surgery through 30 days after the procedure to monitor outcomes and safety. During the study, participants will have their surgeries performed with the robotic system and then be monitored for successful completion of the surgery, any adverse events, and changes in visual acuity. Postoperative eye examinations will be conducted up to 30 days after surgery to assess recovery and safety. The total participation lasts from surgery through this 30-day follow-up period.

Age: 55Years - 80YearsAll GendersPhase Not Applicable
1 location
L

Actively Recruiting

Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.

Age: 18Years +All GendersPhase 3
782 locations
P

Actively Recruiting

Researchers are evaluating a new skin barrier product containing ceramide, virgin coconut oil, and cholesterol to treat adults with skin barrier dysfunction, including mild to moderate psoriasis, atopic dermatitis, contact dermatitis, seasonal xerosis, or clinically evident skin dryness. This pilot randomized controlled trial compares the new product to petrolatum, a standard treatment, to assess effects on skin hydration, sebum, redness, pigmentation, and symptoms like dryness and itch. Participants will apply either the novel barrier product or petrolatum twice daily on the right forearm for 28 days. They will receive supplies of the assigned product in identical containers to keep the study blinded. Follow-up visits occur weekly at weeks 1, 2, and 4, where researchers will measure skin condition and collect questionnaires. Participants will also keep a diary of product application. During each visit, non-invasive tests will measure skin hydration, sebum, redness, and pigmentation using specialized devices. Participants will rate their dryness and itch levels using a visual scale and complete satisfaction questionnaires. Researchers will monitor for any adverse skin reactions. The total participation lasts 28 days with assessments at multiple time points to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase Not Applicable
1 location

1-10 of 11

1